Regulus Therapeutics Inc. (RGLS)

NASDAQ: RGLS · IEX Real-Time Price · USD
0.223
0.007 (3.15%)
Jan 28, 2022 2:42 PM EST - Market open
Market Cap32.52M
Revenue (ttm)5.00M
Net Income (ttm)-22.00M
Shares Out145.97M
EPS (ttm)-0.31
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume657,657
Open0.219
Previous Close0.216
Day's Range0.204 - 0.223
52-Week Range0.190 - 2.320
Beta1.97
AnalystsBuy
Price Target1.50 (+573.2%)
Earnings Daten/a

About RGLS

Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that target microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS4326, an anti-miR targeting miR-17, which is in Phase 1 development for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of p...

IndustryBiotechnology
IPO DateOct 4, 2012
CEOJoseph Hagan
Employees25
Stock ExchangeNASDAQ
Ticker SymbolRGLS
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for RGLS stock is "Buy." The 12-month stock price forecast is 1.50, which is an increase of 573.25% from the latest price.

Price Target
$1.50
(573.25% upside)
Analyst Consensus: Buy

News

Regulus (RGLS) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

After losing some value lately, a hammer chart pattern has been formed for Regulus (RGLS), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions...

2 days ago - Zacks Investment Research

Regulus Therapeutics Moves Forward With Next-Gen Compound, RGLS8429 In Kidney Disorder

Regulus Therapeutics Inc (NASDAQ: RGLS) has completed a pre-investigational new drug (Pre-IND) meeting with the FDA to obtain input on the Company's RGLS8429 for Autosomal Dominant Polycystic Kidney Dis...

1 week ago - Benzinga

Regulus Therapeutics Announces Successful Completion of Pre-IND Meeting with FDA for RGLS8429

SAN DIEGO, Jan. 20, 2022 /PRNewswire/ --  Regulus Therapeutics Inc.  (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the...

1 week ago - PRNewsWire

Regulus Therapeutics to Present at the H.C. Wainwright Virtual BioConnect Conference

SAN DIEGO, Jan. 4, 2022 /PRNewswire/ --  Regulus Therapeutics Inc.  (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the ...

3 weeks ago - PRNewsWire

Regulus Appoints Mohammad Ahmadian, Ph.D., as Vice President, Chemistry and Pharmaceutical Development

SAN DIEGO, Dec. 3, 2021 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "C...

1 month ago - PRNewsWire

Regulus Therapeutics Announces Presentation at the First Annual Rare & Genetic Kidney Disease Drug Development Summit

SAN DIEGO, Dec. 1, 2021 /PRNewswire/ --  Regulus Therapeutics Inc.  (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the ...

1 month ago - PRNewsWire

Regulus Therapeutics Announces Closing of $34.6 Million Private Placement of Equity

SAN DIEGO, Nov. 30, 2021 /PRNewswire/ --  Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the...

1 month ago - PRNewsWire

Regulus Therapeutics Announces Private Placement of Equity

LA JOLLA, Calif., Nov. 24, 2021 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs...

2 months ago - PRNewsWire

Regulus (RGLS) Reports Q3 Loss, Lags Revenue Estimates

Regulus (RGLS) delivered earnings and revenue surprises of -42.86% and -100.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Regulus Therapeutics Reports Third Quarter 2021 Financial Results and Recent Updates

SAN DIEGO, Nov. 10, 2021 /PRNewswire/ --  Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the ...

2 months ago - PRNewsWire

Regulus Therapeutics Announces Timing for Third Quarter 2021 Financial Results Webcast and Conference Call

SAN DIEGO, Nov. 3, 2021 /PRNewswire/ --  Regulus Therapeutics Inc.  (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the ...

2 months ago - PRNewsWire

5 Penny Stocks To Buy For Under $1 On Webull Right Now

Are these Webull penny stocks to buy or avoid right now? The post 5 Penny Stocks To Buy For Under $1 On Webull Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks....

Other symbols:AIHSBIMIMETXTXMD
2 months ago - PennyStocks

Analysts Estimate Regulus (RGLS) to Report a Decline in Earnings: What to Look Out for

Regulus (RGLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

How The Future Looks For Last Week's Biggest Losers: Futu, Regulus Therapeutics And More

Last week, the five biggest stock market losers declined between about 36% and 26%. Below is a look at each stock and what they may have in the cards going forward.

Other symbols:FUTU
3 months ago - Benzinga

Regulus Therapeutics Announces Strategic Prioritization of RGLS8429, its Next-Generation Candidate for the Treatment ...

SAN DIEGO, Oct. 12, 2021 /PRNewswire/ --  Regulus Therapeutics Inc.  (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the...

3 months ago - PRNewsWire

Regulus Therapeutics' Director David Baltimore Receives 2021 Lasker-Koshland Special Achievement Award in Medical Sci...

SAN DIEGO, Sept. 30, 2021 /PRNewswire/ --  Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the...

3 months ago - PRNewsWire

Regulus Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

SAN DIEGO, Sept. 9, 2021 /PRNewswire/ --  Regulus Therapeutics Inc.  (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the...

4 months ago - PRNewsWire

Regulus (RGLS) Reports Q2 Loss, Misses Revenue Estimates

Regulus (RGLS) delivered earnings and revenue surprises of 0.00% and -100.00%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

5 months ago - Zacks Investment Research

Recap: Regulus Therapeutics Q2 Earnings

Shares of Regulus Therapeutics (NASDAQ:RGLS) fell in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share increased 65.22% year over year to ($0.08), which we...

5 months ago - Benzinga

Regulus Therapeutics Reports Second Quarter 2021 Financial Results and Recent Updates

SAN DIEGO, Aug. 10, 2021 /PRNewswire/ -- Regulus Therapeutics Inc.  (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the ...

5 months ago - PRNewsWire

Regulus Therapeutics Announces Timing for Second Quarter 2021 Financial Results Webcast and Conference Call

SAN DIEGO, Aug, 3, 2021 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "C...

5 months ago - PRNewsWire

3 Popular Penny Stocks For Your August 2021 Watchlist

Looking for popular penny stocks to watch? Check these 3 out The post 3 Popular Penny Stocks For Your August 2021 Watchlist appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStoc...

Other symbols:CIDMMETX
5 months ago - PennyStocks

8 Hot Penny Stocks That You Should Add to Your July Watchlist

With July in full swing, here's 8 penny stocks that investors are watching right now The post 8 Hot Penny Stocks That You Should Add to Your July Watchlist appeared first on Penny Stocks to Buy, Picks, ...

6 months ago - PennyStocks

Regulus Therapeutics Presents Additional Data From Rare Kidney Disease Program

Regulus Therapeutics Inc (NASDAQ: RGLS) announced the presentation of additional data from the first cohort from Phase 1b trial of RGLS4326 for autosomal dominant polycystic kidney disease (ADPKD), as w...

7 months ago - Benzinga

Regulus Therapeutics Presents Additional Data from its Autosomal Dominant Polycystic Kidney Disease (ADPKD) Program a...

SAN DIEGO, June 25, 2021 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "...

7 months ago - PRNewsWire